Program
SAL0167
A development code. Also written as “SAL0167 group”.
Its studies are mostly in Hyperlipidemias, led by Shenzhen Salubris Pharmaceuticals.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Shenzhen Salubris Pharmaceuticals | 11 open or running | phase 1since Jul 17, 2026 | Jul 17, 2026 | Jul 31, 2027phase 1 · NCT07722299 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 17, 2026First study: phase 1 study in HyperlipidemiasFirst studyNCT07722299 · 120 planned · China
Ahead
- Jul 31, 2027Primary completion: phase 1 study in HyperlipidemiasNCT07722299
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07722299Hyperlipidemias · China | 1 | Not yet recruiting | Jul 31, 2027 | 120 |
How it is read
Names in the registry
- “SAL0167 group”, 1 entry
Codes read as this program: SAL0167.
Conditions, from the studies’ own filings
- Hyperlipidemias, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.